资源类型:
期刊
WOS体系:
Review
Pubmed体系:
Journal Article;Review
收录情况:
◇ SCIE
文章类型:
论著,综述
机构:
[1]Department of Orthopedics, The Fourth Hospital of Hebei Medical University, 12 Health Road, Shijiazhuang, Hebei 050011, PR China.
河北医科大学第四医院
骨科
临床科室
[2]Hebei Medical University, 361 Zhongshan East Road, Shijiazhuang, Hebei 050011, PR. China.
ISSN:
2212-1374
摘要:
Osteosarcoma (OS) is the most common primary bone tumour in children and adolescents, with high degree of malignancy and an extremely poor prognosis. Ferroptosis, a non-traditional mode of regulated cell death (RCD) characterised by iron-dependent accumulation of lipid reactive oxygen species (ROS), is closely associated with a variety of cancers. It has been demonstrated that ferroptosis can regulate OS progression and exert an essential role in the treatment of OS, which is potentially of great value. By targeting ferroptosis in OS, the present review article summarises the relevant mechanisms and therapeutic applications along with discussing current limitations and future directions, which may provide a new strategy for the treatment of OS.© 2021 The Author(s).
被引次数:
38
WOS:
WOS:000701284400012
PubmedID:
34345580
中科院分区:
出版当年[2021]版:
大类
|
3 区
医学
小类
|
4 区
肿瘤学
最新[2025]版:
大类
|
3 区
医学
小类
|
3 区
肿瘤学
影响因子:
3.5
最新[2024版]
3.6
最新五年平均
4.491
出版当年[2021版]
4.269
出版当年五年平均
4.072
出版前一年[2020版]
3.4
出版后一年[2022版]
第一作者:
Zhao Jiazheng
第一作者机构:
[1]Department of Orthopedics, The Fourth Hospital of Hebei Medical University, 12 Health Road, Shijiazhuang, Hebei 050011, PR China.
通讯作者:
Feng Helin
通讯机构:
[1]Department of Orthopedics, The Fourth Hospital of Hebei Medical University, 12 Health Road, Shijiazhuang, Hebei 050011, PR China.
推荐引用方式(GB/T 7714):
Zhao Jiazheng,Zhao Yi,Ma Xiaowei,et al.Targeting ferroptosis in osteosarcoma.[J].JOURNAL OF BONE ONCOLOGY.2021,30:doi:10.1016/j.jbo.2021.100380.
APA:
Zhao Jiazheng,Zhao Yi,Ma Xiaowei,Zhang Benzheng&Feng Helin.(2021).Targeting ferroptosis in osteosarcoma..JOURNAL OF BONE ONCOLOGY,30,
MLA:
Zhao Jiazheng,et al."Targeting ferroptosis in osteosarcoma.".JOURNAL OF BONE ONCOLOGY 30.(2021)